{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Andreasson K"],"funding":["Anna-Greta Crafoords Stiftelse för Reumatologisk Forskning","Svenska Läkaresällskapet","NHLBI NIH HHS","National Heart, Lung, and Blood Institute","CSRD VA","Ulla och Roland Gustafssons Donationsfond"],"pagination":["421-427"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11246830"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(7)"],"pubmed_abstract":["Objective
Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).Methods
Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later. A 16S ribosomal RNA gene-based validated microbiota test (GA-map Dysbiosis Index Score [DIS], Genetic Analysis, Oslo, Norway) was used to evaluate for the presence and degree of dysbiosis. Fecal levels of Prevotella copri (P. c"],"journal":["ACR open rheumatology"],"pubmed_title":["Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota."],"pmcid":["PMC11246830"],"funding_grant_id":["K23 HL150237","IK2 CX001717","K23HL150237-01","20192005","784201","K23HL150237‐01"],"pubmed_authors":["Lagishetty V","Alrawi Z","Andreasson K","Holster S","Jacobs JP","Klaassens E","Volkmann ER","Olofsson T","Wallman JK","Hesselstrand R"],"additional_accession":[]},"is_claimable":false,"name":"Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota.","description":"Objective
Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).Methods
Consecutive patients, fulfilling the 2010 American College of Rheumatology/EULAR classification criteria for RA, who started treatment with either MTX or TNFi delivered a stool sample upon initiation of immunosuppression and 3 months later. A 16S ribosomal RNA gene-based validated microbiota test (GA-map Dysbiosis Index Score [DIS], Genetic Analysis, Oslo, Norway) was used to evaluate for the presence and degree of dysbiosis. Fecal levels of Prevotella copri (P. c","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-26T14:09:41.167Z","creation":"2025-04-06T14:30:13.722Z"},"accession":"S-EPMC11246830","cross_references":{"pubmed":["38653503"],"doi":["10.1002/acr2.11673"]}}